Regulatory requirements for clinical trials: A comparison of Australia and the US

21st February 2020 (Last Updated March 13th, 2020 08:53)

The regulatory environment in Australia and New Zealand offers a significant strategic opportunity for international biotech companies wanting a fast and pragmatic regulatory pathway for early phase clinical trials.

Sponsored by Novotech Sponsored by Visit Company
Regulatory requirements for clinical trials: A comparison of Australia and the US
Australia and New Zealand offer an alternative recruitment potential to northern hemisphere seasonal related studies. Credit: Shutterstock.

The regulatory environment in Australia and New Zealand offers a significant strategic opportunity for international biotech companies wanting a fast and pragmatic regulatory pathway for early phase clinical trials.

With streamlined regulatory requirements and the supportive R&D Government refund of up to 41% on clinical research spend, Australia has become a preferred destination for early phase clinical trials.

Importantly Australia and New Zealand also offer alternative recruitment potential to northern hemisphere seasonal related studies.

The number of clinical trials has grown solidly in the last few years in Australia, enjoying a steading +10% growth on average between 2016 and 2018.

While the simplified regulatory framework and cash refund scheme has brought many biotechnology companies to Australia for their first-in-human trials, the phase mix remains balanced over that period with a significant portion of late phase trials also.

The Therapeutics Good Administration (TGA) is the regulatory body in Australia. To conduct a clinical trial in Australia, the trial must have an Australian sponsor. There are two main options for submission of clinical trial proposals, the Clinical Trial Notification (CTN) or the Clinical Trial Exemption (CTX). An IND submission is not necessary to initiate first-in-human clinical trials in Australia.

The simplicity and efficiency of the Australian and New Zealand regulatory and ethics processes often means biotechnology companies can commence a clinical trial in parallel to the preparation of an US IND submission, often commencing dosing within a single review cycle of six to eight weeks from submission.

Timeline estimates for a first-in-human completion in Australia compared with Europe and North America

Clinical trial application requirements in Australia, US and EU

About Novotech

Novotech provides regulatory and clinical consulting services to biotechnology companies through its specialized division CNS BioDesk.

BioDesk offers its clients one of the most experienced and cohesive regulatory, CMC and toxicology expert groups available across three continents.

To learn more or talk to their experts about your clinical trial, visit novotech-cro.com/medical-services

Free Whitepaper

The Trends and Future Trajectory of Biotech Clinical Trials

The COVID-19 pandemic has changed the landscape of clinical trials with innumerable vaccines and therapies racing through trials for market or emergency use approval. Looking forward, these changes are projected to accelerate further with innovation shifting from big pharma to biotechs, leading to a greater need for R&D outsourcing.

Data analyst and business intelligence firm GlobalData has partnered with Novotech, the Asia-Pacific CRO, to compile a white paper that explores some of the trends seen in the past year and outline forecasts for what’s next in the industry. With Asia-Pacific expected to have 24% of the global CRO market by 2024, this white paper also explains why the regions is ideal for outsourcing clinical R&D and how drug development plans help biotechs.